Page 966 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 68 Immunological Renal Diseases 933

17. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of 33. Rauen T, Eitner F, Fitzner C, et al. Intensive Supportive Care plus
idiopathic membranous nephropathy. Kidney Int 2008;73:117–25. Immunosuppression in IgA Nephropathy. N Engl J Med
18. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in 2015;373:2225–36.
idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc 34. Wyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med 2013;368:2402–14.
Nephrol 2010;5:2188–98. 35. Karras A, Jayne D. New biologics for glomerular disease on the horizon.
19. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic Nephron 2014;128:283–91.
membranous nephropathy. Lancet 2002;360:923–4. 36. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of
20. Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: ANCA-associated glomerulonephritis. J Am Soc Nephrol
consensus report. Kidney Int 2013;84:1079–89. 2010;21:1628–36.
21. Fakhouri F, Fremeaux-Bacchi V, Noel LH, et al. C3 glomerulopathy: a 37. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide
new classification. Nature Rev Nephrol 2010;6:494–9. for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
22. De Vriese AS, Sethi S, Van Praet J, et al. Kidney Disease Caused by 38. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus
Dysregulation of the Complement Alternative Pathway: An Etiologic cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med
Approach. J Am Soc Nephrol 2015;26:2917–29. 2010;363:211–20.
23. Bertino G, Ardiri A, Proiti M, et al. Chronic hepatitis C: This and the new 39. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for
era of treatment. World J Hepatol 2016;8:92–106. maintenance in ANCA-associated vasculitis. N Engl J Med
24. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and 2014;371:1771–80.
ribavirin in haemodialysis patients. Nephrol Dial Transplant 40. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the
2006;21:1444–5. Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med
25. Feng B, Eknoyan G, Guo ZS, et al. Effect of interferon-α-based antiviral 2010;363:343–54.
therapy on hepatitis C virus-associated glomerulonephritis: a 41. Greco A, Rizzo MI, De Virgilio A, et al. Goodpasture’s syndrome: a
meta-analysis. Nephrol Dial Transplant 2012;27:640–6. clinical update. Autoimmun Rev 2015;14:246–53.
26. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C 42. Pusey CD. Anti-glomerular basement membrane disease. Kidney Int
virus-associated mixed cryoglobulinemia with direct-acting antiviral 2003;64:1535–50.
agents. Hepatology 2016;63:408–17. 43. Hahn BH, McMahon MA, Wilkinson A, et al. American College of
27. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of Rheumatology guidelines for screening, treatment, and management of
rituximab following failure of antiviral therapy for hepatitis C lupus nephritis. Arthritis care & research 2012;64:797–808.
virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 44. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League
2012;64:835–42. Against Rheumatism and European Renal Association-European Dialysis
28. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with and Transplant Association (EULAR/ERA-EDTA) recommendations for
Peg-interferon-ribavirin in refractory hepatitis C virus-associated the management of adult and paediatric lupus nephritis. Ann Rheum Dis
cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67:1431–6. 2012;71:1771–82.
29. Lan X, Rao TK, Chander PN, et al. Apolipoprotein L1 (APOL1) Variants 45. Mok CC. Towards new avenues in the management of lupus
(Vs) a possible link between Heroin-associated Nephropathy (HAN) and glomerulonephritis. Nature Rev Rheumatol 2016;12:221–34.
HIV-associated Nephropathy (HIVAN). Front Microbiol 2015;6:571. 46. Tektonidou MG, Dasgupta A, Ward MM. Risk of End-stage Renal Disease
30. Booth JW, Hamzah L, Jose S, et al. Clinical characteristics and outcomes in Patients with Lupus Nephritis, 1970 to 2015 A systematic review and
of HIV-associated immune complex kidney disease. Nephrol Dial Bayesian meta-analysis. Arthritis Rheumatol 2016;68:1432–41.
Transplant 2016;31:2099–107. 47. Mouthon L, Bussone G, Berezne A, et al. Scleroderma renal crisis. J
31. Nobakht E, Cohen SD, Rosenberg AZ, et al. HIV-associated immune Rheumatol 2014;41:1040–8.
complex kidney disease. Nature Rev Nephrol 2016;12:291–300. 48. Francois H, Mariette X. Renal involvement in primary Sjogren syndrome.
32. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA Nature Rev Nephrol 2016;12:82–93.
nephropathy: rationale, clinicopathological correlations, and classification.
Kidney Int 2009;76:534–45.